112 related articles for article (PubMed ID: 22246586)
21. Eicosapentaenoic acid (EPA) efficacy for colorectal aberrant crypt foci (ACF): a double-blind randomized controlled trial.
Higurashi T; Hosono K; Endo H; Takahashi H; Iida H; Uchiyama T; Ezuka A; Uchiyama S; Yamada E; Ohkubo H; Sakai E; Maeda S; Morita S; Natsumeda Y; Nagase H; Nakajima A
BMC Cancer; 2012 Sep; 12():413. PubMed ID: 22992267
[TBL] [Abstract][Full Text] [Related]
22. Identification of High-Risk Aberrant Crypt Foci and Mucin-Depleted Foci in the Human Colon With Study of Colon Cancer Stem Cell Markers.
Gupta B; Das P; Ghosh S; Manhas J; Sen S; Pal S; Sahni P; Upadhyay AD; Panda SK; Gupta SD
Clin Colorectal Cancer; 2017 Sep; 16(3):204-213. PubMed ID: 27789195
[TBL] [Abstract][Full Text] [Related]
23. Aberrant crypt foci as precursors of the dysplasia-carcinoma sequence in patients with ulcerative colitis.
Kukitsu T; Takayama T; Miyanishi K; Nobuoka A; Katsuki S; Sato Y; Takimoto R; Matsunaga T; Kato J; Sonoda T; Sakamaki S; Niitsu Y
Clin Cancer Res; 2008 Jan; 14(1):48-54. PubMed ID: 18172251
[TBL] [Abstract][Full Text] [Related]
24. Aberrant crypt foci: are they intermediate endpoints of colon carcinogenesis in humans?
Gupta AK; Schoen RE
Curr Opin Gastroenterol; 2009 Jan; 25(1):59-65. PubMed ID: 19114775
[TBL] [Abstract][Full Text] [Related]
25. Rectal aberrant crypt foci (ACF) as a predictor of benign and malignant neoplastic lesions in the large intestine.
Kowalczyk M; Orłowski M; Klepacki Ł; Zinkiewicz K; Kurpiewski W; Kaczerska D; Pesta W; Zieliński E; Siermontowski P
BMC Cancer; 2020 Feb; 20(1):133. PubMed ID: 32075595
[TBL] [Abstract][Full Text] [Related]
26. Correlation of the plasma level of insulin-like growth factor-1 with the number of aberrant crypt foci in male individuals.
Takahashi H; Takayama T; Hosono K; Yoneda K; Endo H; Nozaki Y; Fujita K; Yoneda M; Inamori M; Abe Y; Kobayashi N; Kirikoshi H; Kubota K; Saito S; Nakagama H; Nakajima A
Mol Med Rep; 2009; 2(3):339-43. PubMed ID: 21475834
[TBL] [Abstract][Full Text] [Related]
27. The Effect of Low Doses of Acetylsalicylic Acid on the Occurrence of Rectal Aberrant Crypt Foci.
Kowalczyk M; Sigorski D; Dyśko Ł; Zieliński E; Zupanovich Lucka D; Klepacki Ł
Medicina (Kaunas); 2022 Nov; 58(12):. PubMed ID: 36556972
[TBL] [Abstract][Full Text] [Related]
28. The efficacy of a leukotriene receptor antagonist in the treatment of human rectal aberrant crypt foci: a nonrandomized, open-label, controlled trial.
Higurashi T; Arimoto J; Ashikari K; Takatsu T; Misawa N; Yoshihara T; Matsuura T; Fuyuki A; Ohkubo H; Nakajima A
BMC Cancer; 2020 Aug; 20(1):770. PubMed ID: 32807113
[TBL] [Abstract][Full Text] [Related]
29. Efficacy of Difluoromethylornithine and Aspirin for Treatment of Adenomas and Aberrant Crypt Foci in Patients with Prior Advanced Colorectal Neoplasms.
Sinicrope FA; Velamala PR; Song LMWK; Viggiano TR; Bruining DH; Rajan E; Gostout CJ; Kraichely RE; Buttar NS; Schroeder KW; Kisiel JB; Larson MV; Sweetser SR; Sedlack RR; Sinicrope SN; Richmond E; Umar A; Della'Zanna G; Noaeill JS; Meyers JP; Foster NR
Cancer Prev Res (Phila); 2019 Nov; 12(11):821-830. PubMed ID: 31484660
[TBL] [Abstract][Full Text] [Related]
30. Association between factors associated with colorectal cancer and rectal aberrant crypt foci in humans.
Ezuka A; Sakai E; Kawana K; Nagase H; Kakuta Y; Uchiyama S; Ohkubo H; Higurashi T; Nonaka T; Endo H; Takahashi H; Nakajima A
Oncol Lett; 2015 Dec; 10(6):3689-3695. PubMed ID: 26788192
[TBL] [Abstract][Full Text] [Related]
31. Classification of aberrant crypt foci and microadenomas in human colon.
Roncucci L; Medline A; Bruce WR
Cancer Epidemiol Biomarkers Prev; 1991; 1(1):57-60. PubMed ID: 1845171
[TBL] [Abstract][Full Text] [Related]
32. Rectal Aberrant Crypt Foci in Humans Are Not Surrogate Markers for Colorectal Cancer Risk.
Quintanilla I; López-Cerón M; Jimeno M; Cuatrecasas M; Zabalza M; Moreira L; Alonso V; Rodríguez de Miguel C; Muñoz J; Castellvi-Bel S; Llach J; Castells A; Balaguer F; Camps J; Pellisé M
Clin Transl Gastroenterol; 2019 Jun; 10(6):e00047. PubMed ID: 31136360
[TBL] [Abstract][Full Text] [Related]
33. Variational image segmentation for endoscopic human colonic aberrant crypt foci.
Figueiredo IN; Figueiredo PN; Stadler G; Ghattas O; Araujo A
IEEE Trans Med Imaging; 2010 Apr; 29(4):998-1011. PubMed ID: 19923042
[TBL] [Abstract][Full Text] [Related]
34. Emergence of adenomatous aberrant crypt foci (ACF) from hyperplastic ACF with concomitant increase in cell proliferation.
Otori K; Sugiyama K; Hasebe T; Fukushima S; Esumi H
Cancer Res; 1995 Nov; 55(21):4743-6. PubMed ID: 7585496
[TBL] [Abstract][Full Text] [Related]
35. Pre-neoplastic lesion, mucin-depleted foci, reveals de novo high-grade dysplasia in rat colon carcinogenesis.
Cui C; Takamatsu R; Doguchi H; Matsuzaki A; Saio M; Yoshimi N
Oncol Rep; 2012 May; 27(5):1365-70. PubMed ID: 22294266
[TBL] [Abstract][Full Text] [Related]
36. Dietary acrylamide does not increase colon aberrant crypt foci formation in male F344 rats.
Raju J; Sondagar C; Roberts J; Aziz SA; Caldwell D; Vavasour E; Mehta R
Food Chem Toxicol; 2011 Jun; 49(6):1373-80. PubMed ID: 21421017
[TBL] [Abstract][Full Text] [Related]
37. Aberrant crypt foci in colon cancer epidemiology.
Khare S; Chaudhary K; Bissonnette M; Carroll R
Methods Mol Biol; 2009; 472():373-86. PubMed ID: 19107443
[TBL] [Abstract][Full Text] [Related]
38. Constipation, anthranoid laxatives, melanosis coli, and colon cancer: a risk assessment using aberrant crypt foci.
Nascimbeni R; Donato F; Ghirardi M; Mariani P; Villanacci V; Salerni B
Cancer Epidemiol Biomarkers Prev; 2002 Aug; 11(8):753-7. PubMed ID: 12163329
[TBL] [Abstract][Full Text] [Related]
39. Aberrant crypt foci of the colon as precursors of adenoma and cancer.
Takayama T; Katsuki S; Takahashi Y; Ohi M; Nojiri S; Sakamaki S; Kato J; Kogawa K; Miyake H; Niitsu Y
N Engl J Med; 1998 Oct; 339(18):1277-84. PubMed ID: 9791143
[TBL] [Abstract][Full Text] [Related]
40. Chemoprevention of colorectal cancer.
Niitsu Y; Takayama T; Miyanishi K; Nobuoka A; Hayashi T; Kukitsu T; Takanashi K; Ishiwatari H; Abe T; Kogawa T; Takahashi M; Matsunaga T; Kato J
Cancer Chemother Pharmacol; 2004 Sep; 54 Suppl 1():S40-3. PubMed ID: 15309513
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
